Welcome to Scandion Oncology Q3 report 2024. During the Q&A session, participants are able to ask questions by dialing star five, pound key five, on their telephone keypad. Now we'll hand the conference over to CEO François Martelet and CFO Johnny Stilou. Please go ahead. Good morning, everyone, and thank you for the attendance of this quarterly call for 2024. Could I have the next slide, please? Which is the disclaimer, the classical disclaimer that we will not go through. Next slide. So together with me, we have Johnny Stilou, our CFO, and I will go through quickly the clinical updates. Then Johnny will go through the financial performance, and then I will update you about our partnering activities. Next slide, please. Yes. All right, so you can see us. Next slide. Right, so as you most likely all of you know, so we are in colorectal cancer. We are a drug-resistance company, one of the first, actually, companies in this setting. And we have, over the last few years, engaged in a program called CORIST and with our lead compound, SCO-101, which is a small molecule. Together with FOLFIRI, we've been able to work on phase I, then on phase II, and now we are on phase II-A. Certainly, we are expecting the final data to be released early 2025. We have released earlier the top-line data that are positive, phase II-A data, and we will be releasing the final data analysis early 2025, so for colorectal cancer, for the CORIST program. I will go a little bit into more details later on. PANTAX. PANTAX is our clinical trial in pancreatic cancer. This is phase I-B. We have released the data earlier this year that shows good tolerability, good safety, with a combination of nab-paclitaxel, and gemcitabine, and of course, SCO-101. At the same time, we have engaged earlier in gastric cancer, and we've been able to also release some good preclinical data for gastric. Therefore, for this indication, we are ready to engage in a phase I-B/II-A. At the same time, mainly for cost constraint reasons, we have not been able to pursue and to continue the preclinical development program with SCO-201, but this is certainly an asset that could be actually also potentially used in other indications than oncology like HIV. That asset is currently on hold from a preclinical development perspective. Should I have the next slide, please? Right, a bit more details about CORIST. We've been able to release the top-line data earlier in the year. We've been able to show good safety and a good tolerability profile. Something which is very important in oncology is, of course, partial responses. In the last cohort, where we've been able to demonstrate our MTD, we have got two PRs. This is extremely encouraging for us and for the patients, of course. At the same time, we've been able to show a significant overall survival, which is in the range of from eight to 10 months. Also, if we are selecting a subgroup of patients expressing one type of UGT1A1, then we've been able to increase the overall survival up to 13 months, which is significant. I know, of course, that this is on a limited set of patients, but at least we have to start somewhere. Obviously, this can only be encouraging for the future development of our clinical trial. The conclusion is that we've been able to achieve an MTD, maximum tolerated dose, for the four-day schedule using SCO-101 in combination with FOLFIRI, meaning that we have 50% irinotecan dosage and 100% leucovorin and 5-FU. The result is that we have an MTD at 250 mg per day of SCO-101. Altogether, this is extremely encouraging to continue the development of our clinical development plan for colorectal cancer with SCO-101. Next slide, please. This is for Johnny. Johnny, please go ahead. Thank you, François. Yes, this is the financial overview. And as you can see, the quarter, the third quarter of 2024, ended with a net loss of DKK 6.7 million. This is compared to the same quarter last year, where we had a net loss of DKK 10.1 million. The reduction in loss and reduction in cost is driven by reduced clinical cost as our two clinical programs are reduced. Our cash position at the end of September, end of the quarter, ended with a position of DKK 14.8 million. Now, with this number, bear in mind that we have a tax credit due of DKK 5.5 million, which we receive annually due to our clinical cost clinical programs. And this money, DKK 5.5 million, we will receive for this year later in this month in November. But as of end September, we had DKK 14.8 million. With that cash position, we are able to fund the operation into the fourth quarter of next year, 2025. And here on the next slide, you can see graphically the same that our cost is being reduced quarter-over-quarter. And we expect the same reduction, quarter-over-quarter cost, to continue into 2025, which is why, as just mentioned, our current cash position will take us into the fourth quarter of 2025. With that, I will hand the word back to François. Thank you, Johnny. So if I could summarize where we stand now, as you know, we are a drug-resistance company. We are one of the first movers in this direction. And with our SCO-101, potentially, we are a first-in-class drug inhibition company. And we are targeting two targets, ABCG2 and UGT1A1, as you know. So we are really a precision anti-cancer drug company. We've been able to demonstrate good data out of a phase II-A in colorectal cancer, also some good data in phase I-B in pancreatic cancer. And certainly, our compound has a broad commercial potential, not only in those indications, but also in other indications that could be developed further, depending on the financial position. Financially speaking, we've been able to really control costs very drastically. And as Johnny said, we are able to finance a company into the Q4 2025. Obviously, what's next? So we, as most of you have understood, we are now in the middle of the development process of colorectal cancer, having achieved good phase II-A. So now we need to move the pipeline towards phase II-B/III. In order to do that, we certainly need additional funding. And to perform a phase II-B/III in colorectal cancer does require hundreds of hundreds of patients. Therefore, from a financial perspective, we need to have a partner. Given the market conditions, given where we stand as a publicly listed company, a partner is absolutely needed in order to continue this development program. And this is exactly what I am focusing all my efforts together with Johnny and our CMO and our CSO. And on that side, I'm sure you will appreciate some confidential information that I cannot disclose, but be absolutely sure that we are doing our utmost in order to find a partner. And we, of course, we will be releasing good news whenever available. And I will not say more about that, but again, rest assured that our commitment is 100% towards these development activities. Next slide, please. And this will conclude our brief slide set today. And I am open to any questions you may have. Back to you, Operator, please. Thanks. If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. We'll have a brief pause while questions are being registered. There seems to be no questions. So I hand the word back to you, François and Johnny. Thank you to the audience for listening to us today for this important but short call, and again, we will be updating the market as soon as we have news on the business development side. Thank you very much and have a good day.